This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cigna (CI) to Offer Low-Cost Health Plans in 11 Texas Counties
by Zacks Equity Research
Cigna (CI) expects the 2023 Open Enrollment Period to start on Nov 1 for Texas residents.
3 Blue-Chip Stocks to Boost Your Portfolio's Defense
by Derek Lewis
The Fed's ongoing tightening cycle, paired with geopolitical uncertainties and lingering COVID-19 restrictions, has caused many stocks to pull back significantly in 2022. However, blue-chip stocks weather a dark fiscal cloud better than most.
Will UnitedHealth Group (UNH) Beat Q3 Earnings Estimates?
by Zacks Equity Research
UnitedHealth Group's (UNH) third-quarter results are likely to benefit from higher premiums and membership growth in its UnitedHealthcare unit, partly offset by elevated technology investment costs.
Are Investors Undervaluing Humana (HUM) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights NVIDIA, Pfizer, Citigroup, Humana, and Canadian Natural Resources
by Zacks Equity Research
NVIDIA, Pfizer, Citigroup, Humana, and Canadian Natural Resources are included in this Analyst Blog.
Elevance Health's (ELV) Low-Cost MA Plans to Widen U.S. Base
by Zacks Equity Research
Elevance Health (ELV) devises suitable Medicare Advantage plans containing supplemental benefits, which consumers can avail in the 2023 Annual Enrollment Period.
Humana (HUM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $497.04 in the latest trading session, marking a -1.28% move from the prior day.
Top Analyst Reports for NVIDIA, Pfizer & Citigroup
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Pfizer Inc. (PFE) and Citigroup Inc. (C).
Will Humana (HUM) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Humana (HUM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks Investment Ideas feature highlights: Molina Healthcare, McKesson and Humana
by Zacks Equity Research
Molina Healthcare, McKesson and Humana are part of the Zacks Investment Ideas article.
3 Top-Ranked Healthcare Stocks Thriving in 2022
by Derek Lewis
Healthcare stocks generally carry a defensive nature, helping to shield investors from the market's volatility. Demand for the services these companies provide won't be going anywhere anytime soon.
If You Invested $1000 in Humana a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Humana (HUM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $503.78, moving +0.85% from the previous trading session.
Cigna's (CI) New Pathwell Suite to Boost Efficiency, Lower Cost
by Zacks Equity Research
Cigna (CI) expects to bump up its Pathwell suite's availability throughout the next year.
Are Investors Undervaluing Centene (CNC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Humana (HUM) have performed compared to their sector so far this year.
Zacks Industry Outlook Highlights UnitedHealth Group, Humana, Centene and Molina Healthcare
by Zacks Equity Research
UnitedHealth Group, Humana, Centene and Molina Healthcare are part of Zacks Industry Outlook article.
4 HMO Stocks to Watch Despite Escalating Technology Expenses
by Debasmita Chatterjee
A growing customer base and numerous contract wins might drive the Medical-HMO industry. However, high expenses related to technology advancements and a shortage of nurses will dampen margins. Stocks like UNH, HUM, CNC and MOH will likely ride out the industry storms.
Humana (HUM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $493.91, marking a +0.67% move from the previous day.
Company News for Sep 21, 2022
by Zacks Equity Research
Companies in The News Are: F,HUM,CHNG,UNH,CGNX
Humana (HUM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $499.79 in the latest trading session, marking a +0.51% move from the prior day.
Cigna's (CI) Arm Adds Five Digital Health Apps to Its Platform
by Zacks Equity Research
Cigna's (CI) unit bolsters its clinical platform Digital Health Formulary by including five on-line solutions, aiming to relieve people from chronic medical conditions.
Humana (HUM) Surges 8.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Humana (HUM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is Humana (HUM) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Company News for Sep 16, 2022
by Zacks Equity Research
Companies in The News Are: MSFT, HUM, CTRA, ADBE